Abstract: Tacrolimus, a 23-member macrolide lactone discovered in 1984 from the actinomycete Streptomyces tsukubaensis, was the first macrolide immunosuppressant agent. Tacrolimus was first used for patients after liver transplantation to reduce the activity of the patient's immune system and the risk of organ rejection. Oral tacrolimus was recently approved for use in steroid-refractory moderate-to-severe ulcerative colitis in Japan. This review focuses on the clinical efficacy and safety data of tacrolimus in moderateto-severe refractory ulcerative colitis.
Introduction
Tacrolimus, previously known as FK-506, is a 23-member macrolide lactone discovered in 1984 from the actinomycete Streptomyces tsukubaensis 1 ( Fig. 1) . It was the first macrolide immunosuppressant agent. Tacrolimus was first used for patients after liver transplantation to reduce the risk of organ rejection.
2 Since tacrolimus was approved by the Food and Drug Administration (FDA) in 1994 for use in liver transplantation, its approval has been extended to include kidney, heart, bone marrow, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. In terms of inflammatory bowel disease, clinical trials in Crohn's disease (CD) and ulcerative colitis (UC) have been conducted. 3, 4 In Japan, oral tacrolimus (Prograf ® , Astellas Pharma Inc., Tokyo) was approved by the Ministry of Health, Labour and Welfare in 2009 for remission induction therapy in patients with steroid-refractory moderate-to-severe UC. This review focuses on the clinical efficacy and safety of tacrolimus in moderate-to-severe refractory UC.
Mechanism of Action and Pharmacokinetic Profile
Tacrolimus is a calcineurin inhibitor that suppresses pro-inflammatory cytokine production and T-cell activation (Fig. 2) . Tacrolimus binds to an intracellular protein, 12-kDa FK506-binding protein (FKBP12) 5 . A complex of tacrolimus-FKBP12 blocks the phosphatase activity of calcineurin (CaN). This prevents dephosphorylation and translocation of nuclear factor of activated T-cells (NFAT), which suppresses the NFAT-dependent transcription of cytokines such as interleukin (IL)-2, IL-3, IL-4, IL-5, interferon-γ, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor-α. [6] [7] [8] [9] [10] The cascade results in inhibition of T-lymphocyte activation. Tacrolimus also has a local effect at the intestinal lumen via modulation of the expression of local inflammation mediators, which could be of importance in inflammatory bowel disease. 11, 12 Tacrolimus is metabolized predominantly to 13-O-demethyltacrolimus in the liver and intestine by cytochrome P450 3A (CYP3A), and it is eliminated mostly with the bile 13 . Cyclosporine A (CyA) is also a calcineurin inhibitor, although it binds to different target molecules from tacrolimus. Both tacrolimus and CyA have immunosuppressive properties, but tacrolimus is approximately 10 to 100 times more potent than CyA in vitro. 5 Compared with CyA, tacrolimus has the advantage of more predictable intestinal absorption. CyA needs to be administered intravenously to achieve sufficient, stable levels due to its variable intestinal absorption, whereas tacrolimus has better intestinal absorption and is well-absorbed orally even in severe colitis. 
Clinical Studies
One randomized, double-blind, placebo-controlled study and several uncontrolled studies have demonstrated the efficacy of tacrolimus treatment in patients with UC. Ogata et al conducted a randomized, double-blind, placebo-controlled study to determine the effective trough levels of tacrolimus for remission induction therapy in patients with refractory moderate-to-severe UC. 3 The study randomly divided patients into 3 groups according to target blood trough concentrations: a high trough level group (n = 19, 10-15 ng/ml whole blood), a low trough level group (n = 21, 5-10 ng/ml whole blood), and a placebo group (n = 20). Patients received an initial oral dose of 0.05 mg/kg tacrolimus or placebo twice daily. Efficacy was evaluated over the 2-week treatment period based on a disease activity index (DAI) score, which was determined by combining scores of stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment.
14,15 Patients were classified as complete responders (CRs) if all their symptoms disappeared, partial responders (PRs) if all symptoms improved, and non-responders (NRs) if no improvement was observed. Clinical remission was defined as a DAI score #2, with no individual subscore .1. Mucosal healing was defined as an endoscopy subscore ($2 at entry) of 0 or 1. At the end of 2-week treatment, there were no CRs; however, PRs were observed for 68.4% of cases in the high trough level group, 38.1% in the low trough level group, and 10% in the placebo group. There was significant improvement in the high trough level group versus the placebo group. In the high trough level group, 20.0% of patients had clinical remission and 78.9% had mucosal healing. The authors concluded that the optimal target range for remission induction therapy appears to be 10-15 ng/ml in terms of efficacy with 2 weeks of therapy.
Several uncontrolled studies have also evaluated the efficacy of tacrolimus in adult patients with UC [16] [17] [18] [19] [20] [21] (Table 1 ). In terms of children, Bousvaros et al performed an open-label, multicenter study to evaluate the efficacy of oral tacrolimus for remission induction therapy in steroid-refractory severe colitis (including UC, CD, or indeterminate colitis) in children. 22 Patients received tacrolimus, 0.1 mg/kg twice daily, and the dosage was adjusted to achieve blood levels between 10 and 15 ng/mL. Patients who responded by 14 days continued to receive tacrolimus, and 6-mercaptopurine or azathioprine was added as a steroid-sparing agent 4-6 weeks after tacrolimus had been instituted. One patient withdrew after 48 hours. The authors reported that 9 (69%) of 13 patients improved within 14 days of tacrolimus therapy. The short-term responders included 5 (55%) of 9 patients with UC and 4 of 4 patients with indeterminate or Crohn's colitis. They also reported that the initial response rate of oral tacrolimus was similar to that of patients treated with either intravenous CyA or oral CyA. Tacrolimus was continued for 2-3 months in the responders, except for one patient who was given tacrolimus for 11 months. After 12 months of follow-up, 5 (38%) patients were receiving maintenance therapy; the other 4 (28%) responders had undergone colectomy.
Safety Profile
The commonly reported adverse events of tacrolimus are hypomagnesemia, hyperkalemia, hyperglycemia, tremor, paresthesias, headache, diarrhea, hypertension, nausea, and renal dysfunction [16] [17] [18] [19] [20] [21] (Table 1) . Adverse effects are usually dose-related; most are mild and can be managed by reducing the dose of tacrolimus. Therefore, monitoring blood concentrations of tacrolimus is important. In terms of children, Watson et al retrospectively reviewed the medical records of 46 children with steroid-refractory UC treated with oral tacrolimus. 23 Oral tacrolimus was initiated at a dose of 0.1 mg/kg twice daily and titrated to yield trough levels of 10-15 ng/mL for induction and 5-10 ng/mL once in remission. They reported that the common adverse events noted in the first 3 months of tacrolimus therapy were hypertension (52%), tremor (46%), hyperglycemia (36%), headache (24%), infection (22%), and nephrotoxicity, defined as a creatinine .1.5 × baseline creatinine (11%). They reported that most cases of hand tremor and headache resolved spontaneously or upon routine weaning and cessation of tacrolimus.
Bottiger et al reported that the whole blood concentrations of tacrolimus correlate closely to side effects in renal transplantation recipients. 24 They reported that side effects were noted in connection with 76% of tacrolimus concentrations above 30 ng/ml, with 41% of concentrations within the interval of 20-30 ng/ml, with 26% of concentrations within the interval of 10-20 ng/ml, and with only 5.3% of concentrations lower than 10 ng/ml. They concluded that tacrolimus whole blood trough concentrations should preferably be kept below 20 ng/ml to avoid side effects.
Patient Preference and Dosing
In Japan, oral tacrolimus (Prograf ® ) is approved for remission induction therapy in patients with steroidrefractory moderate-to-severe UC. Oral tacrolimus is approved to be administered up to 3 months when it is clinically effective, because most responders achieved clinical remission, mucosal healing, and reduction of steroid dose within 3 months of administration (data not published). Tacrolimus for remission maintenance therapy is not approved in Japan, because the efficacy and safety of tacrolimus for remission maintenance therapy is still unclear. If clinical response is not observed after 2 weeks of tacrolimus administration, administration is discontinued.
The initial dose of oral tacrolimus is 0.025 mg/kg twice daily. The target range for tacrolimus trough level is 10-15 ng/ml in the first 2 weeks. After 2 weeks' administration, the target range for tacrolimus trough level is 5-10 ng/ml to help avoid side effects (Fig. 3) . As with CyA, the scheduled examination of whole blood trough levels and electrolytes with renal function are important to avoid side effects. The following methods are recommended in Japan (Fig. 4 ): the whole blood trough level is measured 12 and 24 hours after the first administration of oral tacrolimus, and the dose is adjusted as needed. More than 48 hours after the first dosage adjustment, the whole blood trough level is measured twice and the dose is adjusted as needed. More than 36 hours after the second dose adjustment, the whole blood trough level is measured once and the dose is adjusted as needed. About 1 week after the third dose adjustment, the whole blood trough level is measured and the dose is adjusted as needed. Four weeks after the first administration of oral tacrolimus, the whole blood trough level is measured once or more a month. The maximum dose of tacrolimus is 0.3 mg/kg per day.
Conclusions
With sufficient knowledge of the adverse effects and appropriate monitoring, oral tacrolimus can be used both safely and effectively. Compared with CyA, The target range for tacrolimus trough levels is 10-15 ng/ml in the first 2 weeks. After 2 weeks' administration, the target range for tacrolimus trough levels is 5-10 ng/ml to help avoid side effects. tacrolimus has the advantage of more predictable intestinal absorption, and it is well-absorbed orally even in severe colitis. Oral tacrolimus is an alternative induction therapy in steroid-refractory moderate-to-severe active ulcerative colitis. Further studies are expected to evaluate the effect of oral tacrolimus as maintenance therapy in addition to induction therapy.
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